SARS-COV-2 vaccine : current biological targets and considerations / Adolfo Garcia-Sastre.
Saved in:
| Other Authors: | |
|---|---|
| Format: | Streaming audio |
| Language: | English |
| Published: |
London :
Henry Stewart Talks,
2020.
|
| Series: | Henry Stewart talks. Biomedical & life sciences collection. Research and clinical interviews.
|
| Subjects: | |
| Online Access: | Henry Stewart Talks: Biomedical & Life Sciences Series |
MARC
| LEADER | 00000nim a2200000 a 4500 | ||
|---|---|---|---|
| 003 | UkLoHST | ||
| 005 | 20220804112520.0 | ||
| 006 | m o h | ||
| 007 | cr nna|||||||| | ||
| 007 | sr |mnnnnnzne| | ||
| 008 | 200404s2020 enk|||||oh | eng d | ||
| 028 | 5 | 0 | |a 8153 |b Henry Stewart Talks |
| 035 | |a (HSTalks)HST8153 | ||
| 040 | |a HSTalks |b eng |d ATU | ||
| 100 | 1 | |a García-Sastre, Adolfo, |e speaker |9 284998 | |
| 245 | 1 | 0 | |a SARS-COV-2 vaccine : |b current biological targets and considerations / |c Adolfo Garcia-Sastre. |
| 264 | 1 | |a London : |b Henry Stewart Talks, |c 2020. | |
| 300 | |a 1 streaming audio file (8 min.). | ||
| 336 | |a spoken word |b spw |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 344 | |a digital | ||
| 347 | |a audio file | ||
| 490 | 1 | |a Research and clinical interviews, |x 2056-452X | |
| 500 | |a Audio interview. | ||
| 500 | |a Title from title frames. | ||
| 505 | 0 | |a Contents: Comparison of SARS-COV-2 with other coronavirus strains -- Targets for a SARS-COV-2 vaccine -- Other considerations once a vaccine has been developed. | |
| 538 | |a Mode of access: World Wide Web. | ||
| 650 | 0 | |a Coronavirus infections. |9 384640 | |
| 650 | 0 | |a Coronaviruses. |9 347261 | |
| 650 | 0 | |a COVID-19 (Disease) |x Prevention |9 782298 | |
| 650 | 0 | |a Vaccines |x Development |9 790081 | |
| 650 | 0 | |a Vaccines |x Research |9 802268 | |
| 650 | 2 | |a Betacoronavirus |x drug effects. |9 520975 | |
| 650 | 2 | |a Communicable Diseases, Emerging. |9 357724 | |
| 650 | 2 | |a Coronavirus Infections. |9 520983 | |
| 650 | 2 | |a COVID-19 |x therapy. |9 520985 | |
| 650 | 2 | |a Drug Development. |9 520361 | |
| 650 | 2 | |a COVID-19 Vaccines. |9 520900 | |
| 650 | 2 | |a COVID-19 |x prevention & control. |9 520898 | |
| 650 | 2 | |a Vaccination. |9 362643 | |
| 650 | 2 | |a SARS-CoV-2. |9 520891 | |
| 650 | 2 | |a Viral Vaccines. |9 366094 | |
| 830 | 0 | |a Henry Stewart talks. |p Biomedical & life sciences collection. |p Research and clinical interviews. | |
| 856 | 4 | 0 | |u http://ezproxy.aut.ac.nz/login?url=https://hstalks.com/bs/4231/ |z Henry Stewart Talks: Biomedical & Life Sciences |
| 856 | 4 | 2 | |u http://ezproxy.aut.ac.nz/login?url=https://hstalks.com/bs/p/1060/ |3 Series |
| 907 | |a .b29964179 |b 27-04-21 |c 29-09-20 | ||
| 942 | |c SA | ||
| 998 | |a none |b 27-04-21 |c m |d 1 |e - |f eng |g enk |h 0 | ||
| 999 | |c 1587464 |d 1587464 | ||